The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
Chris Parker
Consultant or Advisory Role - Algeta; Bayer; BNIT
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi ; Takeda
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - Algeta; Bayer; Janssen; Medivation
Honoraria - Bayer
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer
Research Funding - Algeta; Bayer
David Bottomley
Honoraria - Bayer
Robert E. Coleman
Honoraria - Bayer; Celgene
Expert Testimony - Novartis
Irene Skjorestad
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Mona Wahba
Employment or Leadership Position - Bayer
Sten Nilsson
Consultant or Advisory Role - Algeta
Other Remuneration - Bayer